Julia Salih

Author PubWeight™ 0.96^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.	Int J Cancer	2010	0.96